Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03390894
Recruitment Status : Recruiting
First Posted : January 4, 2018
Last Update Posted : December 10, 2020
Sponsor:
Collaborator:
AECC_Asociación Española contra el Cáncer
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Brief Summary:

This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group.

Patients will be included in this study from the moment of completion of the follow-up of the studies of origin and will be followed for approximately 30 years


Condition or disease
Invasive Breast Cancer Early Stages

Detailed Description:

One consequence of the improvement in survival rates of certain tumors such as breast cancer is the increase in the number of patients available for long-term follow-up in randomized controlled clinical trials. This long follow-up allows an additional long-term evaluation of the efficacy, as well as of the sequelae related to the treatments that may occur beyond the time of the primary analysis.

The target population of the study are all patients who were included in neoadjuvant and adjuvant clinical trials of GEICAM performed by the goup since 1998 in the medical oncology units of the participating sites, ensuring a follow-up of patients of approximately 30 years. This will allow to describe the long-term evolution of the patients with invasive breast cancer in early stages.

The information obtained will be very useful to professionals involved in the diagnosis, treatment and monitoring of breast cancer, hospital managers, patients with this condition and society in general. This study provides data of great interest for the estimation of long-term disease requirements.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 8000 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
Actual Study Start Date : January 18, 2018
Estimated Primary Completion Date : January 2047
Estimated Study Completion Date : January 2048

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer




Primary Outcome Measures :
  1. Event Free Survival (EvFS) in neoadjuvant studies. [ Time Frame: Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately. ]

    The EvFS, is defined as the time from the randomization of the patients in the studies of origin, to the date of one of the following events:

    • Disease progression during neoadjuvant treatment.
    • Disease relapse (local, regional or distant) after curative surgery.
    • Second primary tumors
    • Death due to any cause.

  2. Disease Free Survival (DFS) in adjuvant studies. [ Time Frame: Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately. ]

    DFS is defined as the time from the date of randomization of patients in the studies of origin, to the date of one of the following events:

    • Disease relapse (local, regional or distant) after curative surgery.
    • Second primary tumors
    • Death due to any cause.


Secondary Outcome Measures :
  1. Overall Survival (OS). [ Time Frame: Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately. ]
    Overall Survival (OS) defined as the time from the date of study enrolment to the date of death from any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with invasive breast cancer (early stages) included in neoadjuvant and adjuvant clinical trials with GEICAM's participation.
Criteria

Inclusion Criteria:

  • Patients included in neoadjuvant and adjuvant clinical trials with GEICAM's participation. If any of these patients had taken part or is participating in another clinical trial, she/he is eligible for this trial and her/his information will also be collected.
  • Patients whose death or contact loss has not been previously collected in the databases of the original studies.

Exclusion Criteria:

  • Patient who were not included in the analyses of the original studies due to non-compliance of the eligibility criteria or the original study informed consent withdrawal.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03390894


Contacts
Layout table for location contacts
Contact: Study Project Manager 00346592870 inicio_ensayos@geicam.org
Contact: Start-Up Unit Manager 00346592870 inicio_ensayos@geicam.org

Locations
Show Show 73 study locations
Sponsors and Collaborators
Spanish Breast Cancer Research Group
AECC_Asociación Española contra el Cáncer
Investigators
Layout table for investigator information
Study Director: Study Director Complejo Hospitalario de Especialidades Virgen de la Victoria
Study Director: Study Director Hospital General Universitario Gregorio Marañón
Additional Information:
Layout table for additonal information
Responsible Party: Spanish Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT03390894    
Other Study ID Numbers: GEICAM/2016-03
2017-002850-35 ( EudraCT Number )
First Posted: January 4, 2018    Key Record Dates
Last Update Posted: December 10, 2020
Last Verified: December 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Spanish Breast Cancer Research Group:
Long-term Follow-Up
Invasive Breast Cancer Early Stages
Previous Neoadjuvant treatment
Previous Adjuvant treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases